Search results for "marqueurs"

showing 10 items of 22 documents

Estimating the genetic diversity and structure ofQuercus trojanaWebb populations in Italy by SSRs: implications for management and conservation

2017

Studying the genetic diversity and structure of the current forest populations is essential for evaluating the ability to survive to future biotic and abiotic changes and planning conservation strategies. Quercus trojana is an eastern Mediterranean tree species with a fragmented distribution range, and its westernmost outposts are located in southern Italy. The demand for timber and cropland over the centuries has severely reduced it s occurrence in this part of the range. We assessed the genetic diversity and structure of the extant Italian populations of Q. trojana and derived conservation guidelines. A total of 322 samples were genotyped with six polymorphic nuclear microsatellite marker…

0106 biological sciences0301 basic medicineSettore AGR/05 - Assestamento Forestale E SelvicolturaQuercus trojana Genetic diversity Population structure SSRs markers ConservationQuercus trojanaRange (biology)PopulationConservationPopulation structure010603 evolutionary biology01 natural sciencesGenetic diversity03 medical and health sciencesQuercus trojanaeducationAbiotic componentQuercus trojana diversité génétique structure de populations marqueurs SSRs conservationGlobal and Planetary ChangeGenetic diversityeducation.field_of_studySSRs markersEcologybiologyEcologyForestrybiology.organism_classification030104 developmental biologyMicrosatelliteGene poolSpecies richnessCanadian Journal of Forest Research
researchProduct

Les ambroisies annuelles (Ambrosia artemisiifolia et Ambrosia trifida) : réponse adaptative au désherbage chimique et connectivité des populations da…

2018

The primary aim of this work was to study the risk of resistance evolution to acetolactate synthase (ALS) inhibiting herbicides in mugwort (Ambrosia artemisiifolia L.) through four points: (i) selection pressure (study of the efficacy of a range of ALS-inhibiting herbicides), (ii) the adaptive response capacity of the weed (determination of the variation in sensitivity to ALS inhibitors between plants and implementation of a recurrent selection programme), (iii) a field study (search for resistance to ALS inhibitors in the field in France), (iv) the study of resistance mechanisms (target-linked - TLR - and non-target-linked - NLR - by a transcriptomics approach). The second objective was to…

Ambrosia artemisiifolia L.ambroisiesinhibiteurs de l’ALSmarqueurs microsatellites[SDE] Environmental SciencesALS inhibitors[SDE]Environmental Sciencesherbicide resistanceflux de gènesrésistance aux herbicidesmicrosatellite markersgene flowragweed
researchProduct

Study of leurocyte telomere lenght and transcription in patients in the acute phase of myocardial infarction

2011

Atherosclerosis with cardiovascular complications remains today one of the leading causes of death in developed countries. In this context, development of new biomarkers of atherosclerosis has an important place. Objectives of these biomarkers are: • to identify populations most at risk of developing cardiovascular complications, • to stratify patient groups to optimize their clinical management and therapeutic, • to reveal new therapeutic targets in the treatment of the disease. In this context, we identified three biomarkers of interest, leukocyte telomere length (LTL) and level of expression of leukocyte genes c-Fos (involved in inflammatory processes and oxidative) and OGG1 (necessary r…

Bio-marqueursLongueur des télomères leucocytairesInflammationPathologies athéromateuses[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyC-FosTabacStress oxydatifNo english keywordsInfarctus du myocardeOGG1Statines
researchProduct

Nouvelles stratégies innovantes en immunothérapie

2018

Resume Les progres recents de l’immunotherapie en oncologie avec le developpement des anticorps anti-PD1/PD-L1 revolutionnent la prise en charge oncologique. L’immuno-oncologie se developpe ainsi dans la plupart des types histologiques de cancer. Malgre tout, l’utilisation des anticorps anti-PD1/PD-L1 en monotherapie est limitee par une reponse restreinte a une sous-population de malades representant environ 25-30 % des patients dans la plupart des indications. Le developpement de nouvelles strategies se base sur cette observation. Ainsi on note le developpement de differentes strategies ayant pour objectifs de mieux selectionner les malades ou de combiner les checkpoints inhibiteurs avec d…

BiomarqueursGynecology0303 health sciencesCancer Researchmedicine.medical_specialtybusiness.industryImmunothérapieImmune checkpoint inhibitorsChimio-immunothérapie[SDV.CAN]Life Sciences [q-bio]/CancerHematologyGeneral Medicine3. Good health03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesisMedicineRadiology Nuclear Medicine and imagingImmunotherapybusinessBiomarkersCheckpoint inhibitors030304 developmental biologyBulletin du Cancer
researchProduct

Evaluation of proton MR spectroscopy at 3 Tesla without endorectal coil in patients with a localized prostate cancer treated with exclusive radiother…

2011

Prostate cancer is the most frequent tumour affecting the male population. When the prostate is not removed and is treated with radiation therapy, PSA slowly decreases over time to reach its nadir, even sometimes 18 to 24 months after the completion of radiation therapy without combined androgen suppression therapy. When combined with hormones, PSA falls abruptely with no possibility to perceive the impact of either hormones or radiation effects on PSA.The optimal value of PSA that should be reached after radiation therapy (nadir) and time to this nadir are still unclear.Even when a satisfactory value of the PSA nadir is reached, on-going variations of the PSA and its “bounce” effects, whic…

BiomarqueursRéponse thérapeutique[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyProstate cancerTherapeutic responseRadiotherapySpectroscopieCancer de la prostateIRM fonctionnelle[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyBiomarkersSpectroscopy[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFunctional MRIRadiothérapie
researchProduct

Involvment of docosanoïc acid (C22=0), and of very long chain fatty acids (tetracosanoïc acid (C24=0), hexacosanoïc acid (C26=0) in Alzheimer's disea…

2013

In the brain and in the plasma of patients with Alzheimer’s disease (AD), marked accumulation of C22:0 and of very long chain fatty acids (C24:0 ; C26:0) have been reported. Important decreases of docosahexaenoic acid (DHA; C22:6 n-3) have also been described as well as quantitative and qualitative modifications of plasmalogens. Altogether, these lipid modifications suggest an implication of peroxisomal metabolism disorders in the physiopathology of AD. Therefore, the biological activities of C22:0, C24:0 and C26:0 have been studied on human neuronal cells SK-N-BE. On these cells, the lipotoxicity of fatty acids (C22:0, C24:0 and C26:0) leads to various cellular modifications: topographical…

Biomarqueurs[SDV.SA] Life Sciences [q-bio]/Agricultural sciences[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyHexacosanoic acid (C26:0)Acide hexacosanoique (C26:0)Souris transgénique APP PS1 ΔE9Transgenic mouse APP PS1 ΔE9PeroxisomeMaladie d’AlzheimerAcides gras à très longue chaîneVery long chain fatty acidsLipotoxicitéTetracosanoic acid (C24:0)Docosanoic acid (C22:0)DemenciaDémencesAcide tétracosanoique (C24:0)PeroxysomeAcide docosanoIque (C22:0)Alzheimer’s diseaseBiomarkersLipotoxicity
researchProduct

Estimation of the degrading genetic potential of soil bacterial communities: a new tool for evaluating and predicting soil contamination by organic m…

2007

During the last two centuries, industrialisation has led to increasing contamination of the environment by xenobiotics, notably aromatic compounds (i.e. PAHs, pesticides). These widespread pollutants are a major threat affecting soil quality and human health. In this context, numerous policies have been drawn up notably in Europe, to monitor the threats of pollution to ecosystems and to detect and implement measures to counterbalance the damage. Nevertheless, the European Commission and scientific community are still confronted with a lack of appropriate tools to monitor biodiversity in relation to environmental processes affecting global warming and soil protection. This study proposes too…

COMMUNAUTE BACTERIENNESOIL DNA[SDV] Life Sciences [q-bio][SDE] Environmental SciencesDEGRADATION DE COMPOSES AROMATIQUESMOLECULAR MARKERVOIE DES BETA-KETOADIPATEADN DU SOLBIODIVERSITYMARQUEURS MOLECULAIRESΒ-KETOADIPATE PATHWAYAROMATIC COMPOUNDS DEGRADATIONBACTERIAL COMMUNIT
researchProduct

Genetic and aromatic diversity of the Burgundy truffle

2013

Truffles are ectomycorrhizal Ascomycota fungi belonging to the Tuberaceae family and more specifically to the Tuber genus. More than thirty Tuber species are currently described in Europe. In this thesis, we specifically focused on the Tuber aestivum-uncinatum model. This truffle is commonly called "Burgundy Truffle" and has a gastronomic and cultural interest.The first part of this thesis focused on the taxonomic status of the Burgundy truffle (Tuber uncinatum). For this, we used a multi-marker approach combining several genetic markers commonly used at the interspecific scale. Our analyses showed that the two taxa, Tuber aestivum (summer truffle) and Tuber uncinatum are conspecific.In the…

DiversityAnalyses phylogénétiquesDiversité[SDV.SA] Life Sciences [q-bio]/Agricultural sciencesMicrosatellite markersTuber aestivumTuber uncinatumVolatile organic compoundsPolymorphismeMarqueurs microsatellitesPolymorphismPhylogenetic analysesComposés organiques volatils
researchProduct

Identification of predictive biomarkers for the efficacy of nivolumab in patients with advanced non-small cell cancer.

2019

The recent introduction of immunotherapy has disrupted the management of non-small cell lung cancer (NSCLC). Nivolumab, an antibody targeting the immune checkpoint inhibitor PD-1, has shown remarkable results in seconde-line setting after failure of standard first-line chemotherapy. However, only a quarter of patients benefits from this therapy. To date, no predictive biomarker of the therapeutic efficacy of nivolumab has been identified in a clear and consensual manner. The research for predictive biomarkers of efficacy or resistance to this treatment is, therefore, a major challenge.The emergence of high-throughput sequencing over the past decade has had a significant impact on clinical a…

Predictive modelsBiomarqueursModèles prédictifs[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyLung cancersCancers bronchiquesImmunothérapieNext-Generation sequencingImmunotherapy[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyBiomarkersSéquençage nouvelle génération
researchProduct

Dépistage du cancer du sein : en route vers le futur

2016

Breast cancer remains a potentially lethal disease, which requires aggressive treatments and is associated with long-term consequences. Its prognosis is linked to both tumor biology and burden at diagnosis. Although treatments have allowed important improvements in prognosis over the past 20 years, breast cancer screening remains necessary. Mammographic screening allows earlier stage diagnoses and a decrease of breast cancer specific mortality. However, breast cancer screening modalities should be revised with the objective to address demonstrated limitations of mammographic screening (limited benefit, imperfect sensitivity and specificity, overdiagnoses, radiation-induced morbidity). Furth…

RiskCancer Researchmedicine.medical_specialtyPersonalized[SDV.CAN]Life Sciences [q-bio]/CancerDiseaseRisque03 medical and health sciencesBreast cancer screening0302 clinical medicineBreast cancerBreast cancer[SDV.CAN] Life Sciences [q-bio]/CancerPersonnalisémedicineMammographyRadiology Nuclear Medicine and imaging030212 general & internal medicineIntensive care medicineScreening proceduresCancer du seinBiomarqueursCancer preventionmedicine.diagnostic_testbusiness.industryHematologyGeneral Medicinemedicine.disease3. Good healthClinical trialOncologyDépistage030220 oncology & carcinogenesisScreeningBiomarker (medicine)businessBiomarkers
researchProduct